183 related articles for article (PubMed ID: 16265371)
21. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
[TBL] [Abstract][Full Text] [Related]
22. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
[TBL] [Abstract][Full Text] [Related]
23. Candesartan cilexetil in the treatment of chronic heart failure.
Baguet JP; Barone-Rochette G; Neuder Y
Vasc Health Risk Manag; 2009; 5(1):257-64. PubMed ID: 19436650
[TBL] [Abstract][Full Text] [Related]
24. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Pocock SJ; McMurray JJ; Dobson J; Yusuf S; Granger CB; Michelson EL; Ostergren J; Pfeffer MA; Solomon SD; Anker SD; Swedberg KB
Eur Heart J; 2008 Nov; 29(21):2641-50. PubMed ID: 18819960
[TBL] [Abstract][Full Text] [Related]
25. [Irbasartan in patients with hart failure and preserved left-ventricular systolic function. Results of the I-PRESERVE study].
Preobrazhenksiĭ DV
Kardiologiia; 2009; 49(2):80. PubMed ID: 19254224
[No Abstract] [Full Text] [Related]
26. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Campbell RT; Jhund PS; Castagno D; Hawkins NM; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2012 Dec; 60(23):2349-56. PubMed ID: 23141494
[TBL] [Abstract][Full Text] [Related]
27. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program.
Mitchell GF; Arnold JM; Dunlap ME; O'Brien TX; Marchiori G; Warner E; Granger CB; Desai SS; Pfeffer MA
Eur J Heart Fail; 2006 Mar; 8(2):191-7. PubMed ID: 16188495
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
29. Improving outcomes in chronic heart failure.
Komajda M
Drugs Today (Barc); 2006 Dec; 42 Suppl C():29-36. PubMed ID: 17245479
[TBL] [Abstract][Full Text] [Related]
30. [The I-PRESERVE study].
Trimarco B; Rosei EA
G Ital Cardiol (Rome); 2009 Aug; 10(8):495-8. PubMed ID: 19771745
[No Abstract] [Full Text] [Related]
31. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.
Castagno D; Skali H; Takeuchi M; Swedberg K; Yusuf S; Granger CB; Michelson EL; Pfeffer MA; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2012 May; 59(20):1785-95. PubMed ID: 22575317
[TBL] [Abstract][Full Text] [Related]
32. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV; Desai AS; Givertz MM
J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
[TBL] [Abstract][Full Text] [Related]
33. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Hawkins NM; Wang D; McMurray JJ; Pfeffer MA; Swedberg K; Granger CB; Yusuf S; Pocock SJ; Ostergren J; Michelson EL; Dunn FG;
Heart; 2007 Jan; 93(1):59-64. PubMed ID: 16952975
[TBL] [Abstract][Full Text] [Related]
35. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.
McKelvie RS
Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):9-16. PubMed ID: 19105762
[TBL] [Abstract][Full Text] [Related]
36. Reduced mortality and morbidity with the use of angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
Yusuf S
Herz; 1993 Dec; 18 Suppl 1():444-8. PubMed ID: 8125425
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect?
Mehta PA; McDonagh S; Phillips J; Grocott-Mason R; Dubrey SW
Clin Cardiol; 2009 Sep; 32(9):513-8. PubMed ID: 19743497
[TBL] [Abstract][Full Text] [Related]
38. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
[TBL] [Abstract][Full Text] [Related]
39. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Kenchaiah S; Pocock SJ; Wang D; Finn PV; Zornoff LA; Skali H; Pfeffer MA; Yusuf S; Swedberg K; Michelson EL; Granger CB; McMurray JJ; Solomon SD;
Circulation; 2007 Aug; 116(6):627-36. PubMed ID: 17638930
[TBL] [Abstract][Full Text] [Related]
40. [Candesartan in heart failure: assessment of reduction in mortality and morbidity].
Tsutsui H
Nihon Rinsho; 2007 Apr; 65 Suppl 4():507-12. PubMed ID: 17508585
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
